PDE4A and Alzheimer disease: Targeting one or two mediators of skin inflammation by inhibitors of JAKs, PDE4, calcineurin, as well as the receptor for IL-4 and IL-13 by monoclonal antibodies, has advanced the treatment of AD and other skin inflammatory diseases2.